CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH In a trial randomizing 372 participants to deferiprone or placebo, nigrostriatal iron content decreased more in the deferiprone group than in the placebo group, but that didn’t correlate to a clinical benefit. Instead, 22% of those on the chelator required initiation of dopaminergic therapy versus 2.7% of those in the placebo group.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
